Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: ... (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... and Theravance Inc. (NASDAQ: THRX ). Free research ... . On Tuesday, November 25, 2014, the NASDAQ ... Average edged 0.02% lower, to finish the day at 17,814.94, ...
(Date:11/26/2014)... Nov. 26, 2014  CARsgen, a leader in the ... to treat a variety of cancers, today announced the ... a China -based healthcare private equity ... focused on the development of new therapeutics for liver, ... Cancer Institute and Shanghai Renji Hospital, the company plans ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... November 27, 2014 An inventor from ... embarrassing fact of life, and she wants to lessen ... minutes later, I decided that there needed to be ... said. , Easy to use and producible in design ... a woman’s private areas throughout the day. It avoids ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... 2014 The founders of VIM & VIGR, ... high functioning compression socks, are proud to announce the debut ... innovative Gradient Pressure (TM) knitting technology that is designed to ... VIGR’s commitment to adding flair and style to a product ... caught the eye of a writer at The New ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5
... nifedipine therapy and placebo, researchers say , , WEDNESDAY, Nov. ... used to prevent premature birth when women go into ... at maintaining pregnancy, after the initial spell of preterm ... who conducted the first ever placebo-controlled test of nifedipine ...
... Media coverage of clinical trials does not contain the ... of the coverage received by pharmaceutical and herbal remedy ... Medicine , has revealed that it is rarely possible ... the described research. , Tania Bubela from the University ...
... The American Veterinary Medical,Association (AVMA) Executive Board voted to ... dogs -- ear cropping and tail,docking. , ... AVMA opposes ear cropping and tail,docking of dogs when done ... ear cropping and tail docking from breed standards." , ...
... DRRX ) announced today that management is scheduled to present ... -- 20th Annual Piper Jaffray Health ... -- RBC Capital Markets 2008 ... A live audio webcast of ...
... ingredients can mean healthier eating without the guilt, experts ... A few healthy substitutions in your Thanksgiving recipes can ... sacrificing the taste, says the American Medical Association. ... swapping out a few ingredients with healthier alternatives, you ...
... (Nasdaq: HLTH ) announced today the preliminary results ... of its common stock at a price of $8.80 per ... on November 25, 2008. Based on the preliminary count ... the tender offer, 86,145,082 shares of common stock (including approximately ...
Cached Medicine News:Health News:Drug to Prevent Preterm Labor Shows Little Benefit 2Health News:Misleading media coverage of medicine 2Health News:AVMA Revises Policy on Ear Cropping and Tail Docking 2Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Holiday Meals With a Calorie-Conscious Twist 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 3Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 4
Bravo Vacuum Pump Accessories Kit (One canister, one lid, one "O" ring tube, one tubing set)...
The pouch is designed to protect the Digitrapper. The pouch strap can be worn on a belt loop or carried in a shoulder strap or backpack configuration....
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
...
Medicine Products: